[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].

Abstract excerpt

The 2016 revised WHO classification of tumors of hematopoietic and lymphoid tissues has incorporated novel molecular markers, such as calreticulin (CALR) mutations, for the diagnosis of myeloproliferative neoplasms (MPNs). Typically, CALR mutations are detected in 25%-30% of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) and can lead to frameshifts that produce proteins with a novel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Primary Myelofibrosis
• Share to Calreticulin
• Share to Mutation